Surging ahead in the RSV race, Pfizer buys out a PhII player in $ 525M M&A pact – Endpoints News

As Congress grapples with how to reform and lower prescription drug costs and may have to settle for a $ 35 monthly insulin cap, new research points to the extent to which seniors skip out on their medicines because of high prices.

Under the Medicare Part D standard benefit, beneficiaries who do not receive a low-income subsidy must pay a percentage of a drug’s list price with every prescription fill. For those who are on expensive or “specialty” drugs, these high up-front costs may result in seniors never starting a new drug, which was the case in four different treatment areas that the researchers, led by Vanderbilt’s Stacie Dusetzina and Harvard’s Haiden Huskamp , wrote about in Health Affairs.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 138,400+ biopharma pros reading Endpoints daily – and it’s free.

Leave a Reply

Your email address will not be published.